Literature DB >> 21947831

Relapsed diffuse large B-cell lymphoma: clinical utility of cell of origin.

Julie M Vose.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21947831     DOI： 10.1200/JCO.2011.37.5733

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

Authors:  Umar Farooq; Matthew J Maurer; Carrie A Thompson; Gita Thanarajasingam; David J Inwards; Ivana Micallef; William Macon; Sergei Syrbu; Tasha Lin; Yi Lin; Stephen M Ansell; Grzegorz S Nowakowski; Thomas M Habermann; James R Cerhan; Brian K Link
Journal:  Br J Haematol       Date:  2017-06-27       Impact factor: 6.998

2.  De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.

Authors:  Lapo Alinari; Alejandro Gru; Carl Quinion; Ying Huang; Arletta Lozanski; Gerard Lozanski; Jacqueline Poston; Girish Venkataraman; Eunhye Oak; Friederike Kreisel; Steven I Park; Stephanie Matthews; Jeremy S Abramson; Hana Iris Lim; Peter Martin; Jonathon B Cohen; Andrew Evens; Zeina Al-Mansour; Arun Singavi; Timothy S Fenske; Kristie A Blum
Journal:  Am J Hematol       Date:  2016-06       Impact factor: 10.047

Review 3.  Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.

Authors:  Grzegorz S Nowakowski; Tatyana Feldman; Lisa M Rimsza; Jason R Westin; Thomas E Witzig; Pier Luigi Zinzani
Journal:  Blood Cancer J       Date:  2019-05-16       Impact factor: 11.037

4.  Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.

Authors:  Fangwen Zhang; Ling Li; Lei Zhang; Xin Li; Xiaorui Fu; Xinhua Wang; Jingjing Wu; Zhenchang Sun; Fei Kong; Liangliang Ren; Mingzhi Zhang
Journal:  Blood Lymphat Cancer       Date:  2019-08-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.